טוען...
Trastuzumab: updated mechanisms of action and resistance in breast cancer
HER2-postitive breast cancer has the second-poorest prognosis among breast cancer subtypes. One of the most effective targeted therapies for patients with HER2-positive breast cancer is trastuzumab-based. However, primary or acquired resistance to trastuzumab has been a major obstacle in the clinica...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2012-06-01
|
| סדרה: | Frontiers in Oncology |
| נושאים: | |
| גישה מקוונת: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00062/full |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|